Regeneron Pharmaceuticals, Inc.
REGENERON PHARMACEUTICALS INC (Form: 4, Received: 12/18/2008 16:18:31)
FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response...
0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

YANCOPOULOS GEORGE
2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS INC [ REGN ]
5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
__ X __ Officer (give title below)      _____ Other (specify below)
EVP, CSO, & Pres Regn Res Labs
(Last)          (First)          (Middle)

777 OLD SAW MILL RIVER ROAD
3. Date of Earliest Transaction (MM/DD/YYYY)

12/16/2008
(Street)

TARRYTOWN, NY 10591
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3)
2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8)
4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4)
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   12/16/2008     M (1)    26991   A $7.41   590085   D    
Common Stock   12/16/2008     S (1)    26991   D $16.4   (2) 563094   D    
Common Stock   12/16/2008     M (1)    73009   A $7.41   636103   D    
Common Stock   12/16/2008     F (1)    32946   D $16.42   603157   D    
Common Stock   12/16/2008     F (1)    14922   D $16.42   588235   D    
Common Stock                  4330   I   By 401(k) Plan  

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)
2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8)
5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)
6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)
8. Price of Derivative Security
(Instr. 5)
9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Incentive Stock Option (right to buy)   $7.41   12/16/2008     (1)       26991   (3)     (4) 1/4/2009   Common Stock   26991     (4) 0   D    
Incentive Stock Option (right to buy)   $16.8   12/17/2008        5952         (5) 12/17/2018   Common Stock   5952     (4) 5952   D    
Non-Qualified Stock Option (right to buy)   $7.41   12/16/2008     (1)       73009   (3)     (4) 1/4/2009   Common Stock   73009     (4) 0   D    
Non-Qualified Stock Option (right to buy)   $16.8   12/17/2008        94048         (5) 12/17/2018   Common Stock   94048     (4) 94048   D    

Explanation of Responses:
( 1)  Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
( 2)  The reporting person sold 26,991 shares of Company stock on December 16, 2008 at prices ranging from $16.08 to $16.70. Upon request by the Commission staff, the Company, or a security holder of the Company, we will provide full information regarding the number of shares sold by the reporting person on December 16, 2008 at each separate price.
( 3)  The stock option became exercisable in five equal annual installments, commencing one year after the date of grant.
( 4)  Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is not applicable in this case.
( 5)  The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
YANCOPOULOS GEORGE
777 OLD SAW MILL RIVER ROAD
TARRYTOWN, NY 10591
X
EVP, CSO, & Pres Regn Res Labs

Signatures
/s/**George D. Yancopoulos 12/18/2008
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.